DexCom, Inc. (NASDAQ:DXCM) Shares Purchased by Stableford Capital II LLC

Stableford Capital II LLC boosted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 236.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,477 shares of the medical device company’s stock after acquiring an additional 10,874 shares during the quarter. Stableford Capital II LLC’s holdings in DexCom were worth $1,204,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Versant Capital Management Inc acquired a new stake in DexCom in the fourth quarter valued at about $25,000. Riverview Trust Co lifted its holdings in shares of DexCom by 100.4% in the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after buying an additional 232 shares during the period. Heck Capital Advisors LLC purchased a new stake in shares of DexCom in the fourth quarter valued at approximately $38,000. RPg Family Wealth Advisory LLC acquired a new position in DexCom during the third quarter worth $57,000. Finally, Covestor Ltd raised its position in DexCom by 53.7% in the third quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock worth $64,000 after acquiring an additional 335 shares in the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at DexCom

In other DexCom news, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the transaction, the chief executive officer now owns 319,037 shares of the company’s stock, valued at $27,727,505.67. This trade represents a 9.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the transaction, the executive vice president now owns 71,192 shares in the company, valued at approximately $5,320,178.16. This trade represents a 5.64 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 42,342 shares of company stock worth $3,628,069. Insiders own 0.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on DXCM. Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Citigroup lifted their price target on shares of DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Finally, Royal Bank of Canada reduced their price objective on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Five investment analysts have rated the stock with a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $99.29.

DexCom Stock Performance

Shares of DXCM opened at $86.83 on Friday. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The company’s 50 day simple moving average is $80.49 and its 200 day simple moving average is $76.67. The company has a market capitalization of $33.92 billion, a price-to-earnings ratio of 51.99, a PEG ratio of 2.22 and a beta of 1.12. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.